People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

No significant difference seen between patients with colorectal cancer and color vision deficiency versus those without color vision deficiency.

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...